Page 23 - IMO-2-1

Innovative Medicines & Omics Incretin mimetics in diabetes management

70. Rubino DM, Greenway FL, Khalid U, et al. Effect of 80. Rendell MS. Albiglutide: A unique GLP-1 receptor agonist.
weekly subcutaneous semaglutide vs daily liraglutide on Expert Opin Biol Ther. 2016;16(12):1557-1569.
body weight in adults with overweight or obesity without
diabetes: The STEP 8 randomized clinical trial. JAMA. doi: 10.1080/14712598.2016.1240780
2022;327(2):138-150. 81. Willard FS, Douros JD, Gabe BN, et al. Tirzepatide is
an imbalanced and biased dual GIP and GLP-1 receptor
doi: 10.1001/jama.2021.23619
agonist. JCI Insight. 2020;5(17):e140532.
71. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM,
Segal JB. Glucagonlike peptide 1-based therapies and risk doi: 10.1172/jci.insight.140532.
of hospitalization for acute pancreatitis in type 2 diabetes 82. Ali R., Virendra SA, Chawla PA. Bumps and humps in the
mellitus: A population-based matched case-control study. success of Tirzepatide as the first GLP1 and GIP receptor
JAMA Intern Med. 2013;173(7):534-539. agonist. Health Sci Rev. 2022;4:100032.
doi: 10.1001/jamainternmed.2013.2720 doi: 10.1016/j.hsr.2022.100032
72. Casella S, Galli K. Appendicitis: A hidden danger of GLP-1 83. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment
receptor agonists? J Pharm Technol. 2024;40(2):108-111. with tirzepatide for maintenance of weight reduction in
adults with obesity: The SURMOUNT-4 randomized
doi: 10.1177/87551225231216638
clinical trial. JAMA. 2024;331(1):38-48.
73. Gudin B, Ladhari C, Robin P, et al. Incretin-based drugs and
intestinal obstruction: A pharmacovigilance study. Therapie. doi: 10.1001/jama.2023.24945
2020;75(6):641-647. 84. Mishra R, Raj R, Elshimy G, et al. Adverse Events Related to
doi: 10.1016/j.therap.2020.02.024 Tirzepatide. J Endocr Soc. 2023;7(4):bvad016.
74. Kalas MA, Galura GM, McCallum RW. Medication-induced doi:10.1210/jendso/bvad016z
gastroparesis: A case report. J Investig Med High Impact Case 85. Leon N, LaCoursiere R, Yarosh D, Patel RS. Lixisenatide
Rep. 2021;9:23247096211051919. (Adlyxin): A once-daily incretin mimetic injection for
doi: 10.1177/23247096211051919 type-2 diabetes. P T. 2017;42(11):676-711.
75. Newsome P, Francque S, Harrison S, et al. Effect of 86. Rosenstock J, Raccah D, Korányi L, et al. Efficacy and safety
semaglutide on liver enzymes and markers of inflammation of lixisenatide once daily versus exenatide twice daily in
in subjects with type 2 diabetes and/or obesity. Aliment type 2 diabetes inadequately controlled on metformin: a
Pharmacol Ther. 2019;50(2):193-203. 24-week, randomized, open-label, active-controlled study
(GetGoal-X). Diabetes Care. 2013;36:2945-2951.
doi: 10.1111/apt.15316
doi:10.2337/dc12-2709
76. Kamrul-Hasan ABM, Dutta D, Nagendra L, Bhattacharya S,
Singla R, Kalra S. Efficacy and safety of albiglutide, a once- 87. Lee J, Kim R, Kim MH, et al. Weight loss and side-effects
weekly glucagon-like peptide-1 receptor agonist, in patients of liraglutide and lixisenatide in obesity and type 2 diabetes
with type 2 diabetes: A systematic review and meta-analysis. mellitus. Prim Care Diabetes. 2023;17(5):460-465.
Medicine (Baltimore). 2024;103(25):e38568. doi: 10.1016/j.pcd.2023.07.006
doi: 10.1097/MD.0000000000038568 88. Niedermier V, Ayers G, Springer S. Lixisenatide (adlyxin) for
77. LiverTox: Clinical and Research Information on Drug-Induced type 2 diabetes mellitus. Am Fam Physician. 2017;96(4):257-258.
Liver Injury. Bethesda, MD: National Institute of Diabetes 89. Li W, Zhou Q, Cong Z, et al. Structural insights into the
and Digestive and Kidney Diseases; 2012. Available from: triple agonism at GLP-1R, GIPR and GCGR manifested by
https://www.ncbi.nlm.nih.gov/books/NBK548054 [Last retatrutide. Cell Discov. 2024;10(1):77.
accessed on 2024 Aug 27].
doi: 10.1038/s41421-024-00700-0
78. Ferreira JP, Sharma A, Vasques-Nóvoa F, et al. Albiglutide
in patients with type 2 diabetes and heart failure: A post- 90. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone
hoc analysis from Harmony Outcomes. Eur J Heart Fail. receptor agonist retatrutide for metabolic dysfunction-
2022;24(10):1792-1801. associated steatotic liver disease: A randomized phase 2a
trial. Nat Med. 2024;30(7):2037-2048.
doi: 10.1002/ejhf.2660
doi: 10.1038/s41591-024-03018-2
79. Pandey S, Mangmool S, Parichatikanond W. Multifaceted
roles of GLP-1 and its analogs: A review on molecular 91. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-
mechanisms with a cardiotherapeutic perspective. receptor agonist retatrutide for obesity - a phase 2 trial.
Pharmaceuticals (Basel). 2023;16(6):836. N Engl J Med. 2023;389(6):514-526.
doi: 10.3390/ph16060836 doi: 10.1056/NEJMoa2301972

Volume 2 Issue 1 (2025) 17 doi: 10.36922/imo.4911